BioAtla (NASDAQ:BCAB) Announces Earnings Results, Beats Expectations By $0.08 EPS

BioAtla (NASDAQ:BCAB) posted its earnings results on Thursday. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.08, Zacks reports.

BioAtla Stock Performance

Shares of BioAtla stock traded down $0.02 on Friday, hitting $0.37. The stock had a trading volume of 1,443,415 shares, compared to its average volume of 994,354. The stock has a 50 day moving average of $0.40 and a 200 day moving average of $1.13. The firm has a market capitalization of $18.05 million, a P/E ratio of -0.22 and a beta of 1.19. BioAtla has a twelve month low of $0.24 and a twelve month high of $4.02.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.